# Vincent Verschaeve

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/vincent-verschaeve/

## Facts

| Field | Value |
| --- | --- |
| Citations | 864 |
| Field | Frailty in Older Adults |
| h-index | 15 |
| i10-index | 18 |
| Last Known Institution | Grand Charleroi Hospital |
| OpenAlex ID | https://openalex.org/A5063215946 |
| ORCID iD | 0000-0002-0575-6304 |
| Works | 51 |

## Researcher papers

- [Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers](https://scholariq.org/papers/phase-ii-study-of-everolimus-in-patients-with-locally-advanced-or-metastatic/)
- [Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer](https://scholariq.org/papers/prospective-randomized-study-comparing-docetaxel-estramustine-and-prednisone/)
- [Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial](https://scholariq.org/papers/erdafitinib-versus-pembrolizumab-in-pretreated-patients-with-advanced-or/)
- [Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma](https://scholariq.org/papers/randomized-phase-ii-trial-comparing-axitinib-with-the-combination-of-axitinib/)
- [Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium](https://scholariq.org/papers/adherence-to-geriatric-assessment-based-recommendations-in-older-patients-with/)
- [Phase <scp>II</scp> study of dual phosphoinositol‐3‐kinase ( <scp>PI</scp> 3K) and mammalian target of rapamycin ( <scp>mTOR</scp> ) inhibitor <scp>BEZ</scp> 235 in patients with locally advanced or metastatic transitional cell carcinoma](https://scholariq.org/papers/phase-scp-ii-scp-study-of-dual-phosphoinositol-3-kinase-scp-pi-scp-3k-and/)
- [Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma](https://scholariq.org/papers/randomized-phase-ii-study-of-axitinib-versus-physicians-best-alternative-choice/)
- [Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial](https://scholariq.org/papers/marizomib-for-patients-with-newly-diagnosed-glioblastoma-a-randomized-phase-3/)
- [Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery](https://scholariq.org/papers/determining-clinically-important-differences-in-health-related-quality-of-life/)
- [A Belgian survey on geriatric assessment in oncology focusing on large-scale implementation and related barriers and facilitators](https://scholariq.org/papers/a-belgian-survey-on-geriatric-assessment-in-oncology-focusing-on-large-scale/)
- [Patient factors associated with caregiver burden in informal caregivers of older adults with cancer: A multicentre cross-sectional study](https://scholariq.org/papers/patient-factors-associated-with-caregiver-burden-in-informal-caregivers-of-older/)

## Researcher topics

- [Frailty in Older Adults](https://scholariq.org/topics/frailty-in-older-adults/)
- [Nutrition and Health in Aging](https://scholariq.org/topics/nutrition-and-health-in-aging/)
- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)
- [Cancer survivorship and care](https://scholariq.org/topics/cancer-survivorship-and-care/)
- [Brain Metastases and Treatment](https://scholariq.org/topics/brain-metastases-and-treatment/)

## Researcher university

- [Grand Charleroi Hospital](https://scholariq.org/institutions/grand-charleroi-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.